Glaxosmithkline Plc And Vir Biotechnology, Inc. Entered Into Research And Development Partnership For Influenza Therapeutics Market

Influenza Therapeutics Market

Growing new drug approval for the treatment of influenza is projected to foster the growth of the influenza therapeutics market. For instance, in October 2018, Roche announced that the U.S. Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older. A rising number of clinical pipeline studies is projected to augment the growth of the market. For instance, in January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the treatment of uncomplicated influenza.

In November 2018, the Henry M. Jackson Foundation for the Advancement of Military Medicine, initiated a phase 4 clinical trial study for egg-based influenza vaccines to study the realistic evaluation of influenza vaccine effectiveness in active duty members, military retirees, and other Department of Defense (DOD) beneficiaries

In February 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses

Growing initiatives by various sponsors to conduct phase 1 clinical trials to study the safety parameter of anti-influenza drugs is projected to the growth of the influenza therapeutics market. For instance, in October 2018, Emory University started a phase 1 clinical trial for seasonal influenza vaccine. The study has been designed to evaluate the impact of imprinting and repeated influenza vaccination on adaptive immunity, transcriptomics, and metabolomics.

North America is projected to hold the dominant position in the global influenza therapeutics market owing to the high presence of key players such as Hoffmann-La Roche Ltd. and GlaxoSmithKline plc. Moreover, regulatory agencies select influenza viruses that are required for developing the influenza vaccine. For instance, in March 2018, FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) conducted a meeting to select the influenza viruses for the composition of the influenza vaccine.

Major players engaged in the global influenza therapeutics market include Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., Sandoz International GmbH (Novartis AG), Atriva Therapeutics Gmbh, Life Science Austria (LISA), GE Healthcare Life Sciences, Texas Medical Center, Sanofi Pasteur SA and Mylan, Inc.

Influenza is a highly contagious and dangerous viral disease that has been recently discovered to be responsible for the death of thousands of people every year. This airborne disease affects the respiratory tract and its organs as well as the bloodstream. Since it has the capacity to cause various complications, doctors need all the tools they have in order to contain and eventually eliminate Influenza.

 

Comments

Popular posts from this blog

Growing The Production And Sales Of Racing Cars And High-Performance Vehicles To Boost The Automotive Roller Tappets Market

Medium Voltage Vacuum Contactors Market Report, Shares, Global Opportunity Analysis and Industry Forecast

The Global Achondroplasia Treatment Market Is Witnessing High Demand Owing To the Rise of the Condition and the Focus of the Key Market Players on Discovering Advanced Medical Technologies